Genetic modifications or pharmacological inhibitors of the NLRP3 inflammasome alleviate HFD-induced hepatic steatosis, hepatocyte inflammation, and fibrogenesis [47,48]. This evidence concerns the gene NLRP3 and Hepatic steatosis.